Gå direkt till huvudinnehållet

Idiopatisk lungfibros

Senast uppdaterad: Senast reviderad:
Sakkunnig:

Definition:
Idiopatisk lungfibros (IPF) är ett tillstånd med gradvis ökande fibros i lungorna. Etiologin är okänd.
Förekomst:
Relativt sällsynt. Prevalensen (USA) är beräknad till 14–43 per 100 000 per år och ökar med åldern. Diagnosen ställs oftast i 60-årsåldern.
Symtom:
Huvudsymtomen är kroniska besvär med gradvist ökande andnöd och hosta.
Kliniska fynd:
Kliniska fynd kan vara vilodyspné, takypné, trumpinnefingrar och cyanos.
Diagnostik:
Viktiga diagnostiska undersökningar är DT av torax, spirometri, bronkoskopi med kryobiopsi och eventuellt torakoskopisk lungbiopsi.
Behandling:
Nya läkemedel (pirfenidon och nintedanib) har visat sig kunna bromsa sjukdomsutvecklingen något. Lungtransplantation kan vara aktuellt.
  1. Vårdprogram för Idiopatisk lungfibros. Svensk Lungmedicinsk Förening 2019 slmf.se  
  2. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795–806. PMID: 25976683 PubMed  
  3. Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllärniemi M. Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med. 2013;13:53. Published 2013 Aug 20. PMID: 23962167 PubMed  
  4. King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Seminar. Lancet 2011; 378: 1949-61. PubMed  
  5. Flesch JD, Kreider ME. Idiopathic pulmonary fibrosis. Best Practice, last updated Feb 2017.
  6. Raghu G, Remy-Jardin M, Myers JL, et al.. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; Sep 1;198(5): e44-e68..
  7. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636-643. PubMed  
  8. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136–142. PMID: 16387946 PubMed  
  9. Guerry-Force ML, Müller NL, Wright JL, et al. A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease. Am Rev Respir Dis. 1987;135(3):705–712. PMID: 3826896 PubMed  
  10. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006;61:980-985. PMID: 16844727. PubMed  
  11. Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999; 116: 1168-74. PubMed  
  12. Hunninghake GW, Lynch DA, Galvin JR, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003; 124: 1215-23. PubMed  
  13. Casoni GL, Tomassetti S, Cavazza A et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One. 2014 Feb 28;9(2):e86716. PMID: 24586252 PubMed  
  14. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014. DOI:10.1056/NEJMoa1402582. DOI  
  15. Spagnolo P, Sverzellati N, Rossi G, Cavazza A, et al. Idiopathic pulmonary fibrosis: an update. Ann Med. 2015 Feb;47(1):15-27. PubMed  
  16. Cheng L, Tan B, Yin Y, et al. Short- and long-term effects of pulmonary rehabilitation for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Rehabil. 2018. PMID: 29843523 PubMed  
  17. Dempsey TM, Sangaralingham LR, Yao X, et al. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019; 200: 168-74. pmid:31150266 PubMed  
  18. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9. PMID: 21571362. PubMed  
  19. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. 2014 Nov;2:933-42. doi: 10.1016/S2213-2600(14)70232-2 DOI  
  20. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-87. DOI: 10.1056/NEJMoa1103690. DOI  
  21. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonar fibrosis. N Engl J Med 2014. DOI:10.1056/NEJMoa1402584. DOI  
  22. Flaherty KR, Wells AU, Cottin V et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019 Sep 29. PMID: 31566307 PubMed  
  23. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. AmJ Respir Crit Care Med 2011;184:1390-1394. PMID: 21700909. PubMed  
  24. Raghu G, Rochwerg B, Zhangh Y, et al . An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Resp Crit Care Med 2015; 192: e3-e19. doi:10.1164/rccm.201506-1063ST DOI  
  25. Hansson L, Riise GC. Lungtransplantation. I boken Lungmedicin, red Sandström T, Eklund A. Studentlitteratur 2015: 233-244
  26. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-40. PubMed  
  27. Duck A, Spencer LG, Bailey S et al. Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs. 2015;71(5):1055–1065. PMID: 25533573 PubMed  
  28. Belkin A, Albright K, Swigris JJ. A qualitative study of informal caregivers' perspectives on the effects of idiopathic pulmonary fibrosis published correction appears in BMJ Open Respir Res. 2014;1(1):e000007corr1. BMJ Open Respir Res. 2014;1(1):e000007. Published 2014 Jan 3.
  • Gerdt Riise, docent och överläkare, Avdelningen för lungmedicin, Sahlgrenska universitetssjukhuset, Göteborg
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet